SOPH vs. NUVB, AVXL, ABCL, CVAC, AVBP, COGT, PAHC, RLAY, CDMO, and SANA
Should you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), CureVac (CVAC), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Relay Therapeutics (RLAY), Avid Bioservices (CDMO), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.
SOPHiA GENETICS vs.
Nuvation Bio (NYSE:NUVB) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.
Nuvation Bio has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
Nuvation Bio has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
Nuvation Bio presently has a consensus price target of $7.40, suggesting a potential upside of 195.41%. SOPHiA GENETICS has a consensus price target of $7.40, suggesting a potential upside of 137.18%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than SOPHiA GENETICS.
Nuvation Bio received 28 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. Likewise, 79.66% of users gave Nuvation Bio an outperform vote while only 73.08% of users gave SOPHiA GENETICS an outperform vote.
61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 5.1% of Nuvation Bio shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Nuvation Bio and Nuvation Bio both had 2 articles in the media. SOPHiA GENETICS's average media sentiment score of 0.77 beat Nuvation Bio's score of 0.35 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.
Nuvation Bio has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -110.71%. Nuvation Bio's return on equity of -21.89% beat SOPHiA GENETICS's return on equity.
Summary
Nuvation Bio beats SOPHiA GENETICS on 12 of the 15 factors compared between the two stocks.
Get SOPHiA GENETICS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SOPHiA GENETICS Competitors List
Related Companies and Tools
This page (NASDAQ:SOPH) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SOPH Stock Alerts